PATENT CLAIM ANALYSIS

Application Number: 16212206
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-06
Patent Classification: ["514", "179000"]

Abstract:
What is disclosed is a controlled release pharmaceutical composition comprising a biocompatible and bioerodible semi-solid gel comprising a triglyceride of ricinoleic acid, a gelling agent, bupivacaine and, optionally, a corticosteroid, an analgesic, or an anti-inflammatory agent.

Claim (Index 7):
The pharmaceutical formulation of  claim 1 , wherein less than 80% of the bupivacaine is released from a depot of the semi-solid gel in five days when measured in vitro at 37\u00b0 C.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 98.0
- Lexical Diversity: 1.48276
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15833899', '14839352', '14853776', '15331767', '15644715']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7926577333067404
- 35 USC 102 Novelty (BERT): 0.5678102195219684
- Combined Prediction Score: 0.7701729819282632
- Mean Citation Score: 311.49194
- Max Citation Score: 402.93753
- Similarity Product: 345.80673379173163

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test